ArticleAntimicrobial resistance and infection control2022
Blood bacterial resistant investigation collaborative system (BRICS) report: a national surveillance in China from 2014 to 2019.
Article in Antimicrobial resistance and infection control, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Genomic characterization of extended-spectrum β-Lactamases (ESBLs)-producing Escherichia coli recovered from bloodstream infections in China.BMC microbiology · 2026Article
- China's nationwide antimicrobial resistance surveillance networks: a systematic analysis from One Health perspective.The Lancet regional health. Western Pacific · 2026Review
- Emergence of Polymyxin Resistance Driven by a PhoQ Mutation in KPC-2-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Predictors of mortality in a Chinese medical ICU: a focus on ICU-acquired bloodstream infections.BMC infectious diseases · 2026Article
- An external validation of the population pharmacokinetic models of polymyxin B in critically ill patients.European journal of clinical pharmacology · 2025Article
- Antimicrobial susceptibility of gram-negative strains isolated from bloodstream infections in China: Results from the study for monitoring antimicrobial resistance trends (SMART) 2018-2020.Epidemiology and infection · 2025Article
- Epidemiology and Antimicrobial Resistance of Stenotrophomonas maltophilia in China, 2014-2021.Infectious diseases and therapy · 2025Article
- Distribution and Antibiotic Resistance Analysis of Bloodstream Infection Pathogens in Yibin, Sichuan.Infection and drug resistance · 2025Article
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Dynamic cytokine profiles of bloodstream infection caused by Klebsiella pneumoniae in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Genomic and immunocyte characterisation of bloodstream infection caused by Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2024Article
- GC-IMS facilitates identification of carbapenem-resistant Klebsiella pneumoniae in simulated blood cultures.AMB Express · 2024Article
- In Vitro Antibacterial Activity of Ceftobiprole and Comparator Compounds against Nation-Wide Bloodstream Isolates and Different Sequence Types of MRSA.Antibiotics (Basel, Switzerland) · 2024Article
- Linezolid Resistance Genes and Mutations among Linezolid-SusceptibleAntibiotics (Basel, Switzerland) · 2024Article
- Extended-Spectrum β-Lactamase-ProducingRisk management and healthcare policy · 2024Article
- Characteristics of Immunocytes and Cytokines in Patients with Bloodstream Infections Caused by Carbapenem-ResistantInfection and drug resistance · 2024Article
- Analysis of the Association Between Antimicrobial Resistance Genes and Virulence Factors in ST11 and Non-ST11 CR-KP Bloodstream Infections in the Intensive Care Unit.Infection and drug resistance · 2024Article
- Eugenol works synergistically with colistin against colistin-resistantMicrobiology spectrum · 2023Article
- CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients-a multicentre study approach, 2021-2022.The Journal of antimicrobial chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 20 institutions in 1 country.
Funding
Abstract
backgroundIn this first national bloodstream infection (BSI) surveillance program in China, we assessed the composition of pathogenic bacteria and the trends for antimicrobial susceptibility over a 6-year period in China.
methodsBlood bacterial isolates from patients at hospitals participating in the Blood Bacterial Resistant Investigation Collaborative System (BRICS) were collected from January 2014 to December 2019. Only the first isolate of a species per patient was eligible over the full study period. Antibiotic-susceptibility testing was conducted by agar-dilution or broth-dilution methods as recommended by the Clinical and Laboratory Standards Institute (CLSI). WHONET 5.6 was used to analyze data.
resultsDuring the study period, 27,899 bacterial strains were collected. Gram-positive organisms accounted for 29.5% (8244) of the species identified and Gram-negative organisms accounted for 70.5% (19,655). The most-commonly isolated organisms in blood cultures were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococci, and Acinetobacter baumannii. The prevalence of multidrug-resistant organisms, such as E. coli, K. pneumoniae, A. baumannii was higher in tertiary hospitals, whereas extended-spectrum, β-lactamase-producing E. coli (ESBL-E. coli), carbapenem-resistant A. baumannii were more prevalent in economically-developing areas. The prevalence of methicillin-resistant S. aureus declined from 39.0% (73/187) in 2014 to 25.9% (230/889) in 2019 (p < 0.05). The prevalence of ESBL-E. coli dropped from 61.2% (412/673) to 51.0% (1878/3,683) over time (p < 0.05), and carbapenem-resistant E. coli remained low prevalence (< 2%; 145/9944; p = 0.397). In contrast, carbapenem-resistant K. pneumoniae increased markedly from 7.0% (16/229) in 2014 to 19.6% (325/1,655) in 2019 (p < 0.05).
conclusionE. coli and K. pneumoniae were the leading causes of BSI during the 6-year study period. The major resistant pathogens declined or remained stable, whereas carbapenem-resistant K. pneumoniae continued to increase, which poses a great therapeutic challenge for BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.